Loading...
AMYT logo

Amryt Pharma plcInforme acción NasdaqGS:AMYT

Capitalización bursátil US$940.7m
Precio de las acciones
n/a
US$20.75
n/adescuento intrínseco
1Y86.5%
7D0.7%
1D
Valor de la cartera
​
Ver

Amryt Pharma plc

Informe acción NasdaqGS:AMYT

Capitalización de mercado: US$940.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amryt Pharma (AMYT) Resumen de Acciones

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. Saber más

Análisis fundamental de AMYT
Puntuación del snowflake
Valoración2/6
Crecimiento futuro5/6
Rendimiento pasado0/6
Salud financiera4/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 53.88%

Los beneficios han crecido un 34.4% al año en los últimos 5 años

Análisis de riesgos

No se han detectado riesgos en AMYT a partir de nuestros controles de riesgos.

AMYT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Competidores de Amryt Pharma plc

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Amryt Pharma
Precios históricos de las acciones
Precio actual de la acciónUS$14.70
Máximo en las últimas 52 semanasUS$14.77
Mínimo de 52 semanasUS$6.41
Beta0.75
Cambio en 1 mes0.96%
Variación en 3 meses-0.14%
Cambio de 1 año86.55%
Variación en 3 añosn/a
Variación en 5 añosn/a
Variación desde la OPV84.91%

Noticias y actualizaciones recientes

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.

Recent updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.
Seeking Alpha • Dec 09

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline.

Rentabilidad de los accionistas

AMYTUS PharmaceuticalsMercado US
7D0.7%5.4%1.2%
1Y86.5%44.3%28.7%

Rentabilidad vs. Industria: AMYT superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 44.3% el año pasado.

Rentabilidad vs. Mercado: AMYT superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.

Volatilidad de los precios

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement0.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de AMYT ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AMYT ha disminuido de 16% a 0% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
2015289Joe Wileywww.amrytpharma.com

Resumen de fundamentos de Amryt Pharma plc

¿Cómo se comparan los beneficios e ingresos de Amryt Pharma con su capitalización de mercado?
Estadísticas fundamentales de AMYT
Capitalización bursátilUS$940.67m
Beneficios(TTM)-US$790.00k
Ingresos (TTM)US$243.62m
3.9x
Ratio precio-ventas (PS)
-1,191x
Ratio precio-beneficio (PE)

¿Está AMYT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AMYT
IngresosUS$243.62m
Coste de los ingresosUS$111.31m
Beneficio brutoUS$132.32m
Otros gastosUS$133.11m
Beneficios-US$790.00k

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-0.012
Margen bruto54.31%
Margen de beneficio neto-0.32%
Ratio deuda/patrimonio64.3%

¿Cómo se ha desempeñado AMYT a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/04/14 09:53
Precio de las acciones al final del día2023/04/11 00:00
Beneficios2022/09/30
Ingresos anuales2021/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Amryt Pharma plc está cubierta por 8 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Michelle GilsonCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.
Andrew YoungDavy